COMPARE · Data as of August 21, 2026
AHR vs MPT
Verdict: Side-by-side breakdown using the Bull Rankings model. AHR scored 78.0, MPT scored 67.0 — AHR leads.
Compare another set
Different reporting periods. AHR's fundamentals are as of June 2026, but MPT's are as of March 2026 — a 3-month gap. Growth, margin and valuation figures below therefore describe different windows and aren't strictly like-for-like.
AHR
American Healthcare REIT, Inc.
43.3Fin
$55.93 · $12.2B
fundamentals as of
Strength gap
26.4
MPT leads
MPT
Medical Properties Trust, Inc.
69.7Fin
$4.12 · $2.5B
fundamentals as of
At a glance · who leads each dimension, on the model's own rules
- Fastest growthAHR+9.1%
- Strongest balance sheetAHR0.42
Side by side · every name on one set of axes
Fundamentals, head-to-head
AHR
MPT
1.8%C+
Yield
8.6%A-
+9.1%B
Rev
-2.4%D+
0.42A
D/E
2.16C
Winner per row is the stronger grade; where grades tie, the better figure breaks it. A true tie or a missing value shows no highlight.
The companies
AHRAmerican Healthcare REIT, Inc.
Why now
REIT - Healthcare Facilities · market cap $12.2b. 5% off the 52-week high of $58.70. 15 sell-side analysts rate this a Strong Buy with a mean 1-yr target of $63.67 (implying +14% upside).
Moat
Moat signals from the quantitative card are modest — profitability and capital efficiency are middle-of-pack. The thesis here depends on softer factors (switching costs, brand, distribution, regulatory protection) not captured by the quality-growth screen.
Risk
Net margin 4.8% is thin — operating leverage cuts both ways; input-cost inflation or pricing pressure hits the bottom line first. ROE 4% is below the long-run sustainable threshold of ~10% — capital efficiency would need to improve for the equity base to compound at the market rate.
MPTMedical Properties Trust, Inc.
Why now
REIT - Healthcare Facilities · market cap $2.5b. Down 36% from 52-week high of $6.47 — deep drawdown territory. 7 sell-side analysts rate this a Hold with a mean 1-yr target of $5.11 (implying +24% upside).
Moat
Turnaround / out-of-favor name — GAAP-unprofitable for now, so the durability case is forward-looking: it rests on a recovery (margin normalization, a cyclical upturn or restructuring) or an un-monetized asset (IP / network effects / first-mover position) rather than on current reported results.
Risk
D/E 2.16 is elevated — limits strategic flexibility and raises refinancing exposure if rates stay higher for longer. Currently unprofitable (margin -2.7%) — path to GAAP profitability is the core thesis risk. Down 36% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up.
Verdict — model-derived comparison
Generating verdict… typically 5–10 seconds
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.